Construction to start on GCP2 Production Facility at Takeda Ireland Ltd site
Takeda Pharmaceutical Company Limited has announced that a groundbreaking ceremony has been held for its new production facility at the existing Grange Castle site in Ireland. Takeda’s existing footprint at the Grange Castle site will be expanded with the construction of a new standalone, high-containment production facility dedicated to manufacturing its oncology product NINLARO for global markets. The investment will create approximately 40 new jobs over the next two years.
“Our new plant in Grange Castle, Ireland is a strategic investment for Takeda,” said Thomas Wozniewski, Head of Global Manufacturing & Supply. “It will give us the crucial in-house manufacturing capacity to meet the increasing demand for our innovative product NINLARO.”
The construction of the plant, which begins in June 2017, will be managed by Project Management Group with over €40 million investment in total. The plant is scheduled to be completed in Q2 FY18 and become operational to commence shipment of secondary packaged product in the second half of FY18.
The new production facility will be unique in that it will house the Drug Substance, Drug Product, Primary and Secondary Packaging and QC processes all under one roof.
NINLARO was approved in November 2015 by the U.S. Food and Drug Administration (FDA). It is the first and only once-weekly oral proteasome inhibitor launched in the U.S. for the treatment of patients with multiple myeloma who have received at least one prior therapy, enabling an all-oral proteasome inhibitor-based triplet treatment regimen for the first time. Additionally, NINLARO® was approved by the Japanese Ministry of Health, Labour and Welfare in March 2017 and launched in May as the first oral proteasome inhibitor in Japan, indicated in combination with lenalidomide and dexamethasone for patients with relapsed or refractory multiple myeloma.
